The estimated Net Worth of William Frank Iv Hulse is at least $4.21 millió dollars as of 13 March 2024. Mr Hulse owns over 20,381 units of MiMedx Inc stock worth over $2,970,946 and over the last 4 years he sold MDXG stock worth over $465,573. In addition, he makes $775,704 as Gen. Counsel & Sec. at MiMedx Inc.
Mr has made over 8 trades of the MiMedx Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 20,381 units of MDXG stock worth $162,029 on 13 March 2024.
The largest trade he's ever made was selling 20,381 units of MiMedx Inc stock on 13 March 2024 worth over $162,029. On average, Mr trades about 5,211 units every 44 days since 2020. As of 13 March 2024 he still owns at least 479,959 units of MiMedx Inc stock.
You can see the complete history of Mr Hulse stock trades at the bottom of the page.
William F. Hulse IV is the Gen. Counsel & Sec. at MiMedx Inc.
As the Gen. Counsel & Sec. of MiMedx Inc, the total compensation of Mr IV at MiMedx Inc is $775,704. There are 5 executives at MiMedx Inc getting paid more, with Timothy Wright having the highest compensation of $5,069,350.
Mr IV is 47, he's been the Gen. Counsel & Sec. of MiMedx Inc since . There are 21 older and no younger executives at MiMedx Inc. The oldest executive at MiMedx Group, Inc is Neil Yeston, 77, who is the Independent Director.
William's mailing address filed with the SEC is 1775, West Oak Commons Court Northeast, Marietta, Cobb, Georgia, 30062, United States.
Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin és Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MiMedx Inc executives and other stock owners filed with the SEC include: